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1. Introduction
In the comprehensive review entitled ‘The DPNH
dehydrogenase of the mitochondrial respiratory chain’
written more than quarter of a century ago, the
authors stated: ‘‘Thanks to the application of sophis-
ticated techniques, the characteristics of this unusual
and interesting enzyme are now understood, at least
in broad terms, long-standing debates in the literature
have been satisfactorily resolved, and the way now
seems clear for the solution of the remaining prob-
w xlems . . . ’’ 1 . Five years later another scholar of
Complex I has pointed out that ‘‘...since no real
breakthrough in the area have occurred since 1963, it
is difficult to find a fresh approach to the subject’’
Abbreviations: SMP, submitochondrial particles; FP, three
subunit iron–sulfur–flavoprotein derived from Complex I; FMN,
flavin mononucleotide; FAD, flavin adenine dinucleotide; Q,
ubiquinone-10; QH , ubiquinol-10; Q , homologues of2 n
ubiquinone having n isoprenoid units in position 6 of quinone
ring; DB, 2,3-dimethoxy-5-methyl-6-decylbenzoquinone; PB,
2,3-dimethoxy-5-methyl-6-pentylbenzoquinone; HAR, hexam-
 .mineruthenium III ; NEM, N-ethyl-maleimide; rhein, 9,10-dihy-
dro-4,5-dihydroxy-9,10-dioxo-2-anthracene carboxylic acid
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w x2 . Both cited statements still appear to be correct.
Indeed, recent spectacular progress in the structural
w x w xstudies of the mammalian 3 , fungal 4 and prokary-
w xotic 5 proton-translocating NADH–quinone reduc-
tases reveals an outstanding complexity of this
multi-subunit and multi-redox component enzyme. It
has been pointed out that the total protein sequence in
more than 40 different subunits of the mammalian
Complex I exceeds the combined sequences of the
w xconstituent polypeptides of prokaryotic ribosome 3 .
The enzyme bears up to 10 different redox compo-
w xnents: FMN 6 , up to seven distinct iron–sulfur
w xclusters 7–10 and at least two bound ubiquinone
w xspecies 11 . Their operational sequence in electron
transfer from NADH to bulk ubiquinone is not known.
Thus, the key question of how the intramolecular
enzyme redox chemistry is coupled with the vectorial
proton translocation remains a matter of speculation
compared to the recent detailed understanding
w xachieved for Complex III 12,13 and cytochrome
w xoxidase 14,15 .
Reviews during the recent years have focused on
w x w xthe structure 3–5 , iron–sulfur clusters 10 , possible
w xmechanisms of proton translocation 16 and the com-
w xparative molecular biology of the enzyme 3,17 . In
the author’s opinion, however powerful the modern
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 .Fig. 1. Schematic presentation of the concerted operation of Complex I shadowed within the inner mitochondrial membrane. Thick
arrows indicate electron and transmembranous proton transfer pathways. Roman figures stand for numbering of complexes according to
w xthe generally accepted nomenclature 18 . The figures indicating thick arrows correspond to the reaction numbers listed in the third
column of Table 1.
molecular biology techniques are, only their combina-
tion with studies on the functional properties of the
enzyme will eventually provide the complete infor-
mation needed to understand its molecular mecha-
nism and physiological regulation.
This mini-review will attempt to summarize avail-
able information on the catalytic properties of the
enzyme with a special emphasis on the hysteretic
behaviour of the bovine heart mitochondrial Complex
I. It is the author’s goal to emphasize in this review
the complexities in interpretation and difficulties in
the reliable catalytic assays of the mammalian Com-
plex I.
2. Activities of the respiratory chain-linked
NADH–ubiquinone oxidoreductase
The diagram shown in Fig. 1 depicts the simple
text-book presentation of the mammalian respiratory
Notes to Table 1:
aArrows “ and ⁄ above figures stand for the forward and reverse reactions, respectively. NADH, succinate, ubiquinol and cytochrome
c oxidation and ATP synthesis are considered as the forward reactions.
bOnly rotenone is included as the specific inhibitor acting on Complex I ‘Q-junction site’. More than a dozen of other rotenone-like
 w x . w x w xinhibitors are known see Refs. 19–23 for cross references . Rhein 24,25 and more recent ADP-ribose 26 were reported as the
competitive inhibitors of NADH binding, thus all the activities with NADH as the substrate are expected to be sensitive to rhein and
ADP-ribose.
c  .  .The NADH oxidase two electron equivalents catalyzed by completely uncoupled AS–SMP at 258C pH 8.0 is taken as arbitrary unit
 . y11.00 . This corresponds to the average specific activity routinely measured in our laboratory of about 1 mmol of NADH oxidized min
y1 w x  .mg protein 27 . The relative figures presented in this column should be considered as provisional. The actual values "5–20%
depend on a number of factors, such as ionic composition of the assay mixture, respiratory control ratio of particular preparation, etc. The
relative activities are referred to those measured under ‘optimal conditions’.
d  .Aerobic NADH oxidation seen either without added electron acceptors NADH–dehydrogenases or in the presence of either rotenone or
 .antimycin A, or myxothiasol or cyanide SMP, Complex I .
eType 1 dehydrogenases, high molecular mass enzyme preparations solubilized from the membranes by treatment with detergents or
w xphospholipase 28–33 . The preparations are free of phospholipids and ubiquinone and in contrast to Complex I are rotenone-insensitive
due to either preparative modification or deficiency in some subunits. Type 2 dehydrogenases, low molecular mass three-subunit
w xiron–sulfur flavoprotein catalyzing oxidation of NADH by artificial electron acceptors 34–36 . The enzyme is evidently a modified















Reactions catalyzed by the preparations of the bovine heart mitochondrial NADH–ubiquinone oxidoreductases different degree of resolution
bReaction Reaction pathway according Preparations capable of the reaction Specific inhibitors Relative specific
to numbering of partial activity in
areactions shown in Fig. 1 submitochondrial
c .partial SMP
“ “ “ c1 NADH–oxidase 1“2“3 Intact mitochondria; SMP Rotenone; antimycin A; 1.00
cyanide
“ “
2 NADH–cytochrome c reductase 1“2 Resolved NADH–cytochrome reductase Rotenone; antimycin A; 0.04
myxothiasol
“
3 NADH–ubiquinone reductase 1 Intact mitochondria; SMP; Complex I Rotenone 1.00
“
4 NADH–artificial acceptor reductase 6 SMP; Complex I; Type 1 and Type 2 None
d .a ferricyanide NADH dehydrogenases 9.00
 .  .b hexammineruthenium III ; 10.00
e .  .c O superoxide generation 0.0052
“q  .5 NADH–acylpyridine NAD 6 ? SMP; Complex I; Type 1 and Type 2 None 1.30
 .transhydrogenase NADH dehydrogenases
“ ⁄
6 NADH–fumarate oxidoreductase 1 “ 4 SMP Rotenone; all the inhibitors 0.015
of Complex II
7 Reverse electron transfer
“ ⁄ ⁄
q .a ATP-driven reduction of NAD 1 “ 4 coupled with 5 Intact mitochondria; coupled SMP in Rotenone; all the inhibitors 0.25
by succinate presence of the ubiquinol of complex II; inhibitors of
oxidase inhibitors F –F –ATPase; uncouplerso 1
“ ⁄ ⁄
 .b ATP-driven rotenone-senstive 4 “ 6 coupled with 5 Coupled SMP The same as 7a 0.27
ferricyanide reductase
⁄ “ “ “q .c Succinate-supported NAD 1 coupled with4“2“3 Intact mitochondria; coupled SMP The same as 7a except for 0.25
 qreduction Dm -dependent Fo–F1–ATPase inhibitorsH
qubiquinol–NAD oxidoreductase;
.aerobic reverse electron transfer
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Table 2
w x  a .Relative affinities of nucleotides to the enzyme in forward and reverse reactions 37,38,26 SMP , pH 8.0, 258C
Reaction
b qcNADH“Q QH “NAD2
Coupled Uncoupled
q .  .  .  .K mM 7 NADH 7 NADH 7 NADm
q .  .  .K mM 1.250 NAD 40 NADHi
d .  .K for ADP-ribose mM competitive inhibition 24 25 no inhibitioni
a w xAS-submitochondrial particles 27 with a respiratory control ratio of 7.
bIn the presence of antimycin A and 0.1 mM Q .1
cATP-driven, succinate-supported reverse electron transfer.
dNADH oxidase reaction.
chain composed of five well-defined complexes I–V
according to the nomenclature by Green’s school
w x.18 , which may or may not be involved in the
catalytic activity of Complex I per se depending on
the assay employed. Some general properties of the
complete NADH oxidase and partial reactions cat-
alyzed by Complex I within the inner mitochondrial
membrane or by the preparations at different degrees
of resolution are summarized in Table 1 and briefly
discussed below. The important point to be empha-
sized is that all the reactions which involve
 .  .ubiquinone oxidoreduction site s 1–3, 6, 7, Table 1
demonstrate abnormal kinetics unless the enzyme
preparations are subjected to reductive–oxidative
 .  .pulse activation before assay see Section 4 . The
data collected in Tables 1 and 2 are characteristics
only for fully activated Complex I.
2.1. NADH oxidase
Oxidation of the intramitochondrial NADH by di-
atomic oxygen consists of concerted operation of
 .three individual complexes Fig. 1 . The turnover
number of Complex I within the complete respiratory
 .chain of uncoupled submitochondrial particles SMP
at 258C is around 1P104 miny1, assuming an aver-
age NADH oxidase activity of 1 mmol NADH oxi-
dized miny1 mgy1 protein and the enzyme content
 . y1FMN-based of 0.1–0.15 nmol mg protein. The
iron–sulfur clusters of Complex I are almost com-
pletely reduced under the steady-state aerobic cou-
w xpled or uncoupled NADH oxidation 39 thus indicat-
ing that Complex I is not rate-limiting during NADH
oxidation by the respiratory chain. The rotenone-sen-
sitive NADH–external Q oxidoreductase activity in1
SMP is close to or even lower than that of NADH
oxidase. Hence, oxidation of the terminal-reduced
component of Complex I by the endogenous
ubiquinone appears to be the rate-limiting step of the
overall NADH oxidase.
Oligomycin, a specific inhibitor of the F proton-o
conductive part of ATP synthase, causes strong inhi-
bition of respiration in some types of SMP which is
w xcompletely relieved by uncouplers 40 thus inducing
a state of ‘respiratory control’. NADH oxidase of
SMP routinely prepared in the author’s laboratory
show the oligomycin-induced respiratory control ratio
of 5–10, depending on the particular batch of heavy
mitochondria from which SMP are prepared.
NADH oxidase of coupled SMP in the presence
.of oligomycin is a useful assay system for studies of
Complex I under conditions where the enzyme oper-
ates as a proton-pump.
2.2. NADH–cytochrome c oxidoreductase
This activity involves simultaneous operation of
Complex I and III and it is seen only in the resolved
preparations of the respiratory chain obtained after
w xtreatment with the detergents 41 . Cytochrome c is
located on the external surface of the inner mitochon-
drial membrane in the intramembranous space of
.intact mitochondria and thus the inside-out SMP do
not catalyze the antimycin A-sensitive NADH–cyto-
chrome c reductase reaction. The reaction does occur
in the classical Keilin–Hartree heart muscle SMP
w xpreparations 42 where NADH oxidase activity is
stimulated 2–3 times by externally added cytochrome
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w xc 43 . Since the inner mitochondrial membrane is not
permeable for NADH, antimycin A-sensitive
NADH–cytochrome c reductase activity can be taken
as a measure of ‘open’ membrane fragments present
in a particular SMP preparation. The antimycin A-
sensitive NADH–cytochrome c reductase is clearly
different from the inhibitor-insensitive NADH–cyto-
chrome c reductase activities catalyzed by some solu-
w xble preparations of NADH dehydrogenase 28–36 .
The latter are evidently the fragments of intact Com-
plex I and in the reactions catalyzed by those prepara-
tions cytochrome c serves just like other artificial
 .electron acceptors see Section 2.4.1 .
2.3. NADH–ubiquinone oxidoreductase
Due to insolubility of the natural ubiquinones in
aqueous solutions the ‘minimal natural’ reaction is
usually followed using their artificial homologues
 .  .Q , Q , Q or analogues PB, DB, duroquinone0 1 2
w x44,45 as electron acceptors. The proton transloca-
tion coupled with NADH–artificial quinone oxido-
reductase was originally observed in intact mitochon-
w x w xdria 46 , Complex I containing liposomes 47 and
w xrecently in SMP 48 .
A straightforward interpretation of the initial rate

— acceptor concentration dependence the standard
.approach in enzymology for both purified dispersed
and membrane-bound Complex I is far from being
trivial.
First, it is not known whether the reaction between
added acceptor and the enzyme terminal electron
donor includes binding of external quinone at the
 .specific site. Reoxidation of the Q pool SMP or10
 .of tightly bound ubiquinol Complex I by added
water soluble quinones or both may equally be opera-
tive during steady-state NADH oxidation.
Second, depending on the particular quinone ac-
ceptor and its concentration, a significant fraction of
the overall reaction is rotenone-insensitive. This is in
contrast to the NADH oxidase reaction which shows
a residual rotenone-insensitive activity of no more
than f1% the latter is, at least partially, due to the
direct reaction of dioxygen with some redox compo-
 . .nent s of the enzyme . The rotenone-insensitive frac-
tion depends linearly on the concentration of added
 .quinone within the solubility limits , and thus the
true saturation characteristics of the rotenone-sensi-
 .tive reaction K , V cannot be obtained by sim-m max
ple algebraic substraction. Additional difficulties lies
in the strong difference between the temperature de-
pendencies of the rotenone-sensitive and rotenone-in-
sensitive reactions. For example, in the presence of
90 mM Q at 208C NADH oxidation catalyzed by1
isolated Complex I is 35% rotenone-sensitive and at
388C the reaction is 92% rotenone-sensitive, whereas
the overall NADH–Q reductase activities at those1
temperatures are 0.34 and 2.8 mmol NADH oxidized
miny1 mgy1 protein, respectively.
The third complication in quantitative and qualita-
tive interpretation of the NADH–quinone reductase
reaction is that the diagram shown in Fig. 1 may
oversimplify the real operative mechanism of the
respiratory chain. Several lines of evidence suggest
that the direct interaction between Complex I and
w xComplex III exists 49,50 . The natural ubiquinone
reductase reaction may be a result of concerted one-
electron reduction of Q or QP by the dehydrogenase
itself which produces either ubisemiquinone or
ubiquinol and by cytochrome b at center i of Com-
plex III, which provide the second electron to com-
plete the two-electron reduction of original quinone
to quinol. In fact such a mechanism has been postu-
lated in the original version of Mitchell’s Q-cycle
w x51 . The observations of partial inhibition of
w xNADH–quinone reductase activities 52,53 by sev-
eral specific inhibitors of Complex III are in line with
such a proposal, although the hypothetical structural
similarity of the ubiquinonerubiquinol binding sites
w xshared by Complexes I and III 53,54 can also
explain this partial inhibition.
Because of the growing interest in NADH dehy-
drogenase activity alteration during the ageing pro-
w xcess and diseases involving Complex I 19,55 some
indirect calculation-based methods for the measure-
ments of true NADH–ubiquinone reductase activity
w xhave been offered 56,57 . However, the reliable
quantitative measurements of the enzyme activity is
still problematic.
2.4. NADH–artificial acceptor reductases
2.4.1. Ferricyanide reductase
SMP, Complex I, Type 1 and Type 2 NADH
dehydrogenases catalyze rapid reduction of ferri-
cyanide by NADH. This one-electron acceptor has
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been routinely used in the earlier numerous studies
w xdirected to isolation of pure enzyme 58 . The reac-
tion is evidently abbreviated compared to the natural
electron pathway. What particular component of the
enzyme that donates electrons to ferricyanide is not
known, although there are strong reasons to believe
that FMN is the reactive site since the reaction is
readily catalyzed by the simplest catalytically compe-
tent fragment of Complex I, Type 2 dehydrogenase
w x36 , containing the iron–sulfur clusters with the mid-
point redox potential of y410 mV and y465 mV
w x59 , i.e., not reducible by NADH. The kinetic char-
acteristics of the NADH–ferricyanide reductase reac-
tion differ qualitatively for preparations of different
degree of resolution. In SMP and Complex I, the
reaction is strongly inhibited by excess of substrate
 .NADH . The standard graph of the dependence of
initial rate on NADH concentration dependence at
any fixed ferricyanide concentration appears as a
steep curve with the maximum position which de-
w xpends on the acceptor concentration 60 . Such a
behaviour has been interpreted as competition be-
tween ferricyanide and NADH for a common redox
 .site presumably FMN located in a deep cleft within
w xthe quaternary protein structure 60 . Indeed, the solu-
ble FP shows much less pronounced steepness of
w xthose curves 61 , however, the enzyme turnover
number calculated on the basis of FMN content in FP
is about 10 times less than that in the parent Complex
w xI or SMP 61 . The specific activity of NADH–ferri-
cyanide reductase catalyzed by FP is significantly
w xincreased in the presence of guanidine chloride 62 .
It should be noted that the turnover numbers of the
enzyme in the NADH–ferricyanide reductase reac-
tion are controversial, because of extreme difficulties
in the reliable double extrapolation to V . Themax
actual kinetic data appear as a set of steep curves
which can hardly be approximated as hyperbolaes
within any range of substrate and acceptor concentra-
tions. It is worth noting that the non-enzymatic oxida-
tion of NADH by ferricyanide becomes significant
when the concentrations of the latter reaches the
millimolar range.
( ) [ ]2.4.2. Hexammineruthenium III reductase 38,63
Similar to ferricyanide, hexammineruthenium III
 .HAR was found to be an efficient electron acceptor
for the enzyme in inside-out SMP and isolated Com-
w xplex I, but not in intact mitochondria 38 . The reac-
tion is rotenone-insensitive and is not coupled with
proton-translocation. No inhibition of the reaction by
either NADH or by the electron acceptor was re-
vealed in a wide concentration range. For SMP or
Complex I the double-reciprocal plots 1r˝ versus
1rNADH at various HAR concentrations give a se-
ries of straight lines intersecting in the third quadrant,
thus supporting a mechanism in which the reduced
enzyme–NADq complex is oxidized by HAR through
the operation of a single redox site before NADq
dissociation.
 .Type 2 three subunits iron–sulfur flavoprotein
dehydrogenase is also highly reactive with this elec-
w xtron acceptor 63 . In fact, HAR is the only artificial
acceptor which reveal the same turnover numbers of
the enzyme based on FMN content in SMP, Complex
I and FP. In contrast to ferricyanide reduction, guani-
dine does not stimulate but inhibits the NADH–HAR
reductase activity of FP competitively with the elec-
tron acceptor. Due to the simplicity of quantitation of
the kinetic data, the highest reactivity towards the
enzyme, absence of spectral overlap with NADH and
absence of a non-enzymatic reaction, HAR seems to
be a superior choice among a variety of artificial
electron acceptors used for the enzyme assay in the
resolution studies.
2.4.3. Superoxide generation
Oxygen, strictly speaking, is not an ‘artificial’
electron acceptor. Direct reduction of O is perhaps2
 .the main source of ROS reactive oxygen species in
mitochondria. The latter have received a considerable
attention recently because of their possible participa-
tion in destructive damage of mitochondrial DNA,
some enzymes and membranes. The production of
H O by autooxidation at the first coupling site in2 2
w x Pmitochondria was reported many years ago 64 . O2
 .superoxide anion is a stoichiometric precursor of
w xthe mitochondrial H O production 65 and one-2 2
electron reduction of dioxygen by some components
of the respiratory chain was estimated to account for
up to 2% of the respiration under physiological con-
w x ditions 66 . The superoxide dismutase EC
.1.15.1.1 -sensitive NADH- and NADPH-supported
oxidation of adrenaline or reduction of acetylated
cytochrome c with the specific activity of about 1
nmol of OP miny1 mgy1 protein at 308C was ob-2
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served in antimycin A- and rotenone-inhibited SMP
w x67 . The site of superoxide production in Complex I
have not been identified; potentially all the enzyme
w xredox components: FMN 68 , iron–sulfur clusters
w x w x69 and ubisemiquinone 70 can generate the super-
oxide radical. In antimycin A-treated SMP the effect
of rotenone is biphasic: an increase in OP production2
was observed up to an inhibitor concentration well
above the level required to inhibit NADH oxidase
 .0.3 nmolrmg of protein , and a decrease at higher
w xconcentrations 67 . Formation of superoxide radical
in both SMP and isolated Complex I with NADH and
NADPH is biphasic in the double reciprocal plot
 .1rrate versus 1rnucleotide concentration showing
w xtwo apparent K for the substrates 71,72 . Rotenone-m
and uncoupler-sensitive OP generation by ATP-driven2
reverse electron transfer from ubiquinol to some
w xunidentified component was reported 64,73 . The
rate of the energy-dependent reaction was about 20%
of that observed in the presence of NADH plus
 .rotenone and it was strongly stimulated 4–5 times
q w xby NAD 73 . Bound NADP radical was proposed
as the source of superoxide in the reverse electron
transfer reaction as it has been shown for other
w xNAD-dependent dehydrogenases 74,75 .
It worth noting that the specific activity of Com-
plex I in the superoxide generating reactions is about
3 order of magnitude less than that in the NADH–
 .ubiquinone reductase or NADH oxidase SMP and
the reaction is certainly not suitable for catalytic
assay of the enzyme activity. However, OP and H O2 2 2
 .the product of the superoxide dismutase reaction are
potentially involved in numerous physiological and
pathophysiological processes such as signal transduc-
w xtion or oxidative damage 76,77 . If the superoxide
generation is to be considered as the ‘dangerous
leak’, the functional role of some enzyme subunits
which are not directly involved in the electronrpro-
ton transfer reaction may be explained: they could
serve as a protective ‘wrapping’ of the low potential
redox components to prevent a direct reaction with
oxygen. This would also explain why artificial elec-
tron acceptors react at the entry point or at ubiquinone
 .reactive site Q , duroquinone but not at intermedi-1
ate sites. In addition inhibitors interrupting electron
transfer between iron–sulfur centers have not been
found so far: apparently the system is well-protected.
The superoxide generation by SMP or Complex I is
evidently different from that catalyzed by the soluble
FP in the aerobic rotenone-insensitive NADH–
w xquinone reductase reaction 78 .
2.5. Transhydrogenase and other NADP qrNADPH-
dependent reactions
The inner mitochondrial membrane contains two
enzymes capable of transhydrogenase activity. One is
the proton-pumping transhydrogenase containing no
 .redox prosthetic groups EC 1.6.1.1 catalyzing a
direct hydride transfer between the 4A hydrogen of
NADH and 4B hydrogen of NADPH coupled with
q w xvectorial translocation of H 79 . In addition to the
activities discussed in Section 2.4, Complex I and
some simpler preparations catalyze 4B stereospecific
w xFMN-mediated tritium–H O exchange 80,81 and2
q w xoxidation of NADH by acetyl pyridine NAD 62 . It
seems pertinent to note that transhydrogenase activity
 .is not a general property of NADH NADPH -oxidiz-
ing enzymes: for example DT-diaphorase
 NADHrNADPH–quinone oxidoreductase EC
.1.6.99.2 , a homodimeric FAD containing enzyme
catalyzing oxidation of either NADPH or NADH
w x82,83 is not capable of transhydrogenation. The
transhydrogenase activity of Complex I suggests by
itself that the redox potential of FMN is close to that
of the substraterproduct pyridine nucleotide pair. If
the reduction of flavin by NADH would be thermo-
dynamically irreversible the large redox gap between
the reduced enzyme and oxidized pyridine nucleotide
would create considerable restrictions in the subse-
quent electron transfer from the enzyme to the nu-
cleotide substrate. Indeed, the midpoint redox poten-
w xtials of FMN measured directly for Complex I 84
w xand estimated indirectly for FP 85 are close to that
for NADHrNADq pair.
SMP catalyze rotenone-sensitive NADPH oxida-
tion in complete absence of transhydrogenase EC
.1.6.11 activity at much lower rate compare to that
w xfor NADH 86,87 . NADPH dehydrogenase activity
 .increases at acidic pH below 6.0 in contrast to
 .NADH oxidation broad pH optimum at pH 7.5–8.2 .
NADH“acetyl pyridine nucleotide activity is seen
with SMP, Complex I, Type 1 and Type 2 dehydro-
w xgenases 62,88 . The Type 2 enzyme catalyzes the
NADPH“NADq reaction whereas no NADH“
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NADPq or NADPH“NADPq activities could be
w xdetected 62 . Tightly coupled bovine heart SMP
catalyze energy-dependent, succinate-supported,
w 3 x qrotenone sensitive stereospecific 4B- H NAD and
q w xNADP reduction 79,86,89 which is believed to be
a simple reversal of the proton-translocating
 .NADH–ubiquinone reductase reaction see below .
NADPH reduces FMN and Fe–S clusters of the
enzyme. The observation of different reduction of
some Fe–S clusters and studies on inhibition of
NADH and NADPH oxidation by stoichiometric
amounts of the inhibitor piericidin has led Bakker
w x w xand Albracht 90 , van Belzen and Albracht 91 , and
w xvan Belzen et al. 92 to propose a heterodimeric
structure for Complex I which is composed of
wNADH-specific and NADPH-specific protomers 90–
x92 . More recently, the same experimental results
have been reinterpreted to suggest a monomeric
structure of the enzyme containing two FMN and
. w xpresumably two nucleotide binding sites 93 . Stud-
ies of NADH- and NADPH-induced lipid peroxida-
tion in SMP have led to the conclusion that Complex
I is able to distinguish between electron input from
NADH and NADPH by differences in the substrate
w xbinding sites 94 .
The largest subunit of FP which contains FMN and
the iron–sulfur cluster N-3 has been identified to
contain a single NADH-binding site in the mam-
w xmalian and bacterial Complex I 95–98 . On the other
hand, since FP is capable of transhydrogenase activ-
ity it was suggested that FP contains two closely
related active sites: site 1 for NADH and NADPH
dehydrogenation and site 2 for binding a second
w xnucleotide for transhydrogenation 62 . Most recently
a model suggesting two different nucleotide binding
sites operating in the direct and reverse electron
w xtransfer reactions has been proposed 26 . This model
is based on the finding of ‘unidirectional’ effect of
ADP-ribose, which inhibits NADH oxidation in SMP,
Complex I and FP competitively and stimulates the
aerobic succinate-supported energy-dependent re-
w xverse electron transfer 26 . It is pertinent to note that
in addition to the conserved primary sequences of the
w xbovine 51 kDa subunit 3 and its Paracoccus deni-
w x w xtrificans 5 and N. crassa 99 counterparts recog-
nized as the most likely candidates for NADH-bind-
ing site, another segment of sequence that fits to the
nucleotide binding site has been identified in 39 kDa
w xsubunit of bovine Complex I 3 and in the homo-
w xlogues 40 kDa subunit of N. crassa complex 100 .
Summarizing the discussion on NAD and NADP
reactivity it should be emphasized that the questions
of how many nucleotide binding sites are present in
 .Complex I and if more than one their specificity
 .and cooperation if any remain and should be experi-
mentally verified.
2.6. NADH–fumarate oxidoreductase
Since the midpoint redox potential of
 .succinaterfumarate couple f0.00 V is much more
q  .positive than that of NADHrNAD fy0.32 V
w x101 it is expected that fumarate must be an efficient
electron acceptor for NADH oxidation provided that
catalytic mechanism for the equilibration exists. In-
deed it has been shown that when oxidation of
ubiquinol is blocked, SMP exhibit NADH–fumarate
reductase reaction which is sensitive to all the in-
hibitors of Complex I and Complex II. In coupled
SMP oxidation of NADH by fumarate was shown to
w xdrive ATP formation 102 . The absolute specific
activity of SMP in this reaction is quite low 0.015
moles miny1 mgy1 protein at 258C in the presence of
myxothiasol which is about 1.5% of NADH–
ubiquinone reductase, and comparable with the
rotenone-insensitive NADH-induced superoxide gen-
.eration and it is not stimulated by uncouplers. There
are several apparent reasons for such low activity.
First, the kinetic properties of the mammalian Com-
plex II which is capable of fumarate reductase activ-
ity, is evolutionally adjusted for the catalysis of the
physiologically significant direction i. e. succinate
w xoxidation 103 . An interesting diode-like behaviour
of succinate dehydrogenase has been demonstrated
and interpreted as the kinetic restrictions for substrate
 .binding or product release under the conditions of
w xoverpotential driving force 104 . Second, in the
steady-state NADH–fumarate reductase reaction the
ubiquinone pool is reduced. Not only does this de-
crease the availability of an electron acceptor for
Complex I, but also ubiquinol inhibits NADH–
ubiquinone reductase unpublished observation from
.o u r la b o ra to ry . I t a p p e a rs th a t th e
ubiquinonerubiquinol ratio within the membranous
bulk lipid phase regulates the activities of Complexes
I and II not only by the availability of the electron
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 .  .acceptors Q but also by a product QH inhibition2
w x105,106 and by the redox potential-controlled gate
w xmechanism 104 .
2.7. Re˝erse electron transfer
The reversibility of the electron transfer reactions
at the first coupling site of the respiratory chain was
discovered almost forty years ago when Chance and
w xHollunger 107 and independently Klingenberg and
w xSlenczka 108 have shown that addition of succinate
or a-glycerophosphate to mitochondria in State 4
respiration causes an uncoupler-sensitive reduction of
the intramitochondrial pyridine nucleotides. An excel-
lent account of the earlier classical works on the
w xsubject can be found in Refs. 109,110 . The general
properties of the reaction which is now widely used
for studies of Complex I as well as for the reversibil-
ity of proton translocating F –F ATP synthase areo 1
briefly summarized below.
2.7.1. ATP-dri˝en reduction of NAD by succinate
As shown in diagram presented in Fig. 1 and Table
1 the overall reaction in SMP is the result of simulta-
neous operation of three enzyme complexes: Com-
plex II which provides electrons for ubiquinone re-
 .duction, Complex V reversible F –F ATPase whicho 1
q qgenerates Dm , and Complex I which utilizes DmH H
for the ubiquinol–NADq reductase reaction under
the conditions where the ubiquinol oxidase activity is
blocked by inhibitors of Complex III or Complex IV.
In contrast to the relatively invariable specific activi-
ties of different SMP in the NADH–ubiquinone re-
ductase or NADH oxidase reactions considerable
variations in the specific activity of ATP-dependent
reverse electron transfer are scattered in the literature.
Those variations are evidently due to the differences
in proton leakage for different SMP preparations
w x111 and perhaps even more significantly to the
properties of each enzyme participating in the reac-
 .tion. Succinate dehydrogenase Complex II is known
to exist, at least partially, in the tightly bound ox-
aloacetate-deactivated form in most preparations of
w x  .SMP 112,113 . Prolonged incubation 10–30 min in
 .the presence of either the substrate succinate or a
 .competitive inhibitor malonate at rather high tem-
 .perature 208–308C prior to assay is needed to dis-
place the tightly bound oxaloacetate and to reach full
w xcatalytic capacity of the enzyme 112–114 . F –Fo 1
ATPase is also present in most types of SMP in the
 2q.ADP Mg -deactivated state and shows consider-
able lag-phase of the ‘initial’ rate of ATP hydrolysis
in the presence of an ATP-regenerating system added
w xin the ‘kinetic’ excess 115 , phosphoenol pyruvate
 .and pyruvate kinase EC 2.7.1.40 are routinely used
to prevent accumulation of strongly inhibitory ADP
w x.116 . It should be noted that most commercial
preparations of pyruvate kinase are contaminated with
 .lactate dehydrogenase EC 1.1.1.27 . The latter en-
zyme, if present, uses stoichiometrically pyruvate
formed in the pyruvate kinase reaction to oxidize the
NADH formed during ATP hydrolysis thus leading to
an underestimation of the reverse electron transfer
rate. Complex kinetic behaviour of ATP hydrolysis is
also expected for those SMP preparations which con-
w xtain an ATPase protein inhibitor 117 , an intrinsic
component of ATP synthase which interacts with F1
in very complex strongly ionic strength-, pH- and
w xtime-dependent fashion 118 . Also as it will be
discussed in Section 4, Complex I itself in its deacti-
vated form shows complex kinetic behaviour. In the
author’s opinion, the previously reported abnormali-
ties of the ATP-dependent reverse electron transfer
w xreaction 89,119 were due to an interplay of the
factors listed above. It appears that the preparation of
choice for quantitative studies of the reverse electron
w xtransfer is so-called AS-SMP 120 which are essen-
tially free of protein inhibitor and partially deficient
in F . These particles can be artificially coupled by1
w xeither substoichiometric amount of oligomycin 40
 .for the ATP-dependent reaction or by the excess of
the antibiotic for the aerobic ATP-independent reac-
.tion . Under appropriate conditions coupled AS-SMP
catalyze ATP-dependent reverse electron transfer at
the rate equal to about one-fourth of that for forward
w xNADH–ubiquinone or NADH oxidase 27 .
2.7.2. ATP-dri˝en succinate-supported ferricyanide
reduction
This reaction is a variant of that previously dis-
cussed where ferricyanide instead of NADq serves as
the final acceptor for the electrons provided by
ubiquinol and delivered to an unidentified low mid-
point potential redox component of Complex I as a
qresult of the Dm -dependent reverse electron flowH
w x64 . In inside-out SMP the only component which
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 .react with ferricyanide 0.5–1 mM at significant rate
is Complex I as is evident from the about 90%
sensitivity of the ATP-dependent succinate–ferri-
cyanide reductase reaction to rotenone and uncou-
w xplers 27,64 . It is generally believed that ferricyanide
accepts electrons from the same component which
participates in NADH–ferricyanide reductase reac-
 .tion presumably FMN .
2.7.3. Aerobic succinate-supported NAD q or
ferricyanide reduction
Although this reaction was in fact the first experi-
mental proof for the reversibility of coupling site 1
w x107,108 it has not been demonstrated in SMP until
w xrecently 27 . In tightly coupled SMP oxidation the
ubiquinol produced by operation of Complex II cre-
qates Dm through subsequent operation of Com-H
.plex III, cytochrome c and cytochrome c oxidase
which can be used to drive the reverse electron flow
from ubiquinol to NADq. The initial rate of this
uncoupler- and rotenone-sensitive reaction is the same
as that measured under conditions where ubiquinol
oxidase is blocked and Dm q is provided by ATPH
w xhydrolysis 27 . Depending on the concentration of
added N A D q the constant steady-state
q NADHrNAD ratio reached as in intact mitochon-
w x.dria 107–110 , in a first approximation, is a mea-
qsure of the steady-state Dm . The situation, how-H
ever is not as simple as might be expected if Com-
plex I is considered as the catalytic unit which simply
equilibrates NADHrNADq pair with QrQH pool2
qand Dm . It has been shown that the steady-stateH
NADHrNADq ratio can be increased by the addi-
 . w xtion of rotenone low concentrations 121 , an obser-
vation which led to a proposal that interaction of
qrotenone with Complex I is Dm -dependent and theH
increase of NADHrNADq ratio is due to preferential
inhibition of NADH oxidation by the uncoupled ‘sub-
w xpopulation’ of SMP 121 . More detailed quantitation
of the affinity of Complex I to rotenone has revealed
no difference for coupled or uncoupled SMP, al-
though about 10-times difference in the sensitivity of
the forward and reverse electron transfer reactions to
w xthe inhibitor was found 122 . It has been proposed
that different binding sites for ubiquinone and
ubiquinol with different sensitivity to rotenone oper-
ates during catalytic turnovers in NADH oxidation
 . q forward reaction or NAD reduction reverse reac-
.tion . This proposal is corroborated by the recent
observation of the ‘unidirectional’ effect of ADP-
 .ribose the competitive inhibitor of NADH oxidase
which induces an increase of NADHrNADq
steady-state ratio during aerobic succinate-supported
w xreverse electron transfer 26 similar to rotenone.
3. Steady-state kinetic parameters
Table 2 summarizes the apparent affinities of the
 .nucleotides to the membrane-bound Complex I SMP
as determined from the initial rate vs. substrate con-
centration dependencies for the rotenone-sensitive re-
actions. No deviation from the simple hyperbolic
variation in the rate with substrate concentration is
seen for either forward or Dm q-dependent reverseH
reactions, indicating that either a single substrate
binding site operates, or more than one site with no
 .kinetic cooperativity, or two or more sites operate
with absolute cooperativity flip-flop mechanism
w x.123 . The striking difference between the apparent
affinities for NADq as a competitive inhibitor of
 .NADH oxidation 1.2 mM and as a substrate for the
 .reverse electron transfer 7 mM suggest that different
substrate binding sites may be involved in the for-
ward and reverse reactions. This is in accordance
with a unidirectional inhibition of NADH oxidation
w xby its analogue ADP-ribose 26 .
(4. Pre-steady-state kinetics active r inactive
)transition
4.1. Historical
As already mentioned, all the activities and param-
eters described in the previous sections refer to the
‘activated’ NADH–quinone reductase. As will be
outlined in this section most, if not all the prepara-
tions of the mammalian enzyme are heterogeneous
mixtures of active and deactivated forms as evident
from complex kinetics of the initial rate of NADH
oxidation. The abnormal time-course of the reaction
was originally reported in 1950 by Slater who has
observed a lag-phase in the NADH–cytochrome c
reductase catalyzed by Keilin–Hartree heart muscle
preparation in the presence of cyanide reaction 2,
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. w xTable 1 124 . Twelve years later Morrison and King
have claimed their observation on a pronounced lag
in the NADH–cytochrome c reductase activity of the
same preparation which was increased upon thermal
w xdenaturation 125 . Further studies have revealed that
the reaction between NADH dehydrogenase and
 .Complex III i.e., ubiquinone reduction is responsi-
w xble for the observed time lag 126 . The thermally
induced inactivation of particulate and reconstituted
NADH oxidase which was completely restored by the
addition of NADH under aerobic conditions have
w xbeen confirmed by Luzikov’s group 127,128 , who
also found that preheated particles are more sensitive
to the destroying effects of chymotrypsin, oleate and
w xphospholipase 127,128 . They have interpreted their
observations to suggest that the respiratory chain
components exist in activated and non-active forms
in a ratio which depends on the electron transfer rate
w x128,129 . In the papers to resolve the controversial
reports on the sensitivity of NADH oxidase to NEM
w x130,131 , Estabrook et al. concluded that after incu-
bation at 378C ‘‘ . . . the particles remember that they
have been treated at the higher temperature and in
that way retain their sensitivity to inhibition by NEM’’
w x132 . Although the pioneering works of Estabrook et
al. have clearly indicated a heterogeneity of Complex
I within the inner mitochondrial membrane the prob-
lem was somehow ignored up till recently when the
phenomenon was studied in more detail in our labora-
tory. A brief account of those studies is given below
and is summarized in a scheme shown in Fig. 3.
4.2. Phenomenology
Fig. 2 shows schematically a time-course of the
rotenone-sensitive substrate consumption or product
formation in the forward or reverse reactions cat-
alyzed by two different preparations of SMP: ther-
 .mally deactivated curve 1 and thermally deactivated
and further treated with NADH either under aerobic
conditions or in the presence of added quinone curves
.2 . Several points need to be emphasized before
further discussion. All the preparations capable of the
rotenone-sensitive NADH oxidation which assayed in
our laboratory such SMP, Keilin–Hartree particles
w x w x43 , purified NADH–cytochrome c reductase 41
w xand Complex I 133 show qualitatively the same
pattern as depicted in Fig. 2A, whereas neither the
ferricyanide nor HAR–reductase activities of those
preparations and none of the activities of the Type 2
dehydrogenase show lags in their NADH dehydroge-
nase capacity. Also, when Q is employed as electron1
acceptor only the rotenone-sensitive part of the over-
all reaction demonstrates such a behaviour. The
 azero-order rate of NADH oxidation or reduction ˝ ,
.curves 2 are uncoupler-sensitive when tightly cou-
 .  . Fig. 2. Time-course of the reactions catalyzed by active curves 2 and deactivated curves 1 preparations of SMP schematic
.  i . apresentation . The final levels of the rates reached during the reactions ˝ are equal to ˝ . Note the difference in the time scale int“‘
q .  .  .  qpanels A NADH oxidase or NADH–Q reductase, forward reaction and B Dm -dependent ubiquinol–NAD reductase, reverse1 H
.reaction .
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pled particles are assayed, however the activation
half-times are the same for coupled or completely
and partially uncoupled systems. Thus it is safe to
qconclude that the activation is Dm -insensitive. TheH
initial rates of the reactions catalyzed by the prepara-
tions deliberately subjected to thermal deactivation
 i .˝ are very close to zero, whereas those for SMP or0
Complex I as prepared according to the published
procedures show a variety of the initial rates be-
.tween those shown by curves 1 and 2 depending on
the particular preparation. The completeness of acti-
vation by aerobic NADH pretreatment is crucially
dependent on the protein content in the samples. Very
 .low concentrations of NADH 5–10 mM are needed
for complete activation of diluted 5–50 mg of pro-
y1.tein ml samples and much higher NADH is re-
 .quired up to millimolar range when concentrated
suspensions are subjected to activation. This is sim-
ply because a fraction of the activated enzyme formed
during preincubation in concentrated samples rapidly
 .consumes added NADH andror oxygen or quinone
thus preventing further transformation of the residual
inactive enzyme. It should be emphasized that the
reduction per se does not induce the transformation
of inactive enzyme into its active form. No activation
by NADH takes place when the ubiquinone pool is
completely reduced by succinate anaerobically or in
.the presence of cyanide . Thus slow initiating redox
cycle is needed to reach full catalytic capacity of the
enzyme. Finally, it is worthwhile to mention that the
activation half-time under the conditions usually em-
ployed for the NADH oxidase or NADH–ubiquinone
 .reductase assay pHf7.5, 20–278C is rather short
 .5–20 s , thus the phenomenon could be easily over-
looked when the slowly responding registration sys-
tem such as a membrane-coated oxygen-sensitive
 .electrode NADH oxidase or exclusively computer-
ized spectrophotometers are used.
4.3. Deacti˝ation
The only factor strongly affecting transformation
of active enzyme into the inactive form is tempera-
ture. NADq, reduction of endogenous ubiquinone,
NADH under conditions when ubiquinone pool is
reduced, the presence of bivalent cations, addition of
w xthe competitive inhibitor ADP-ribose 26 , dilution or
concentration of the enzyme preparations, anaerobio-
sis, ferricyanide, the presence of the sulfhydryl
reagents separately or in combinations when possi-
.ble do not significantly affect the rate of deactiva-
tion. On the other hand the effect of temperature is
dramatic. An activation energy as high as 270 kJrmol
was determined from the linear Arrhenius plot within
w xthe temperature range of 25–408C 27,133 . A de-
 a .crease of the initial rate ˝ , Fig. 2 of the forward or
reverse electron transfer reactions follows the same
first-order time course with t of about 15 min at1r2
308C. The thermally induced deactivation was origi-
w xnally described as an irreversible process 27 . Closer
examination revealed a constant residual activity of
w xthe thermally deactivated SMP 122 . Therefore the
deactivation process should be considered as sponta-
neous equilibration between two forms of the enzyme
Fig. 3. Hypothetical reaction pathways describing the slow activerinactive enzyme transitions. Figures in italic correspond to the number
of particular step as discussed in the text. E , E , I and R stand for deactivated enzyme, active enzyme, sulfhydryl reagents andin a SH
rotenone, respectively. Different thickness of the arrows emphasize shifts in equilibria of the corresponding reactions. See text for further
explanations.
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 .reaction 1, Fig. 3 . The equilibrium position does not
significantly depend on temperature, whereas the rate
of equilibration strongly does. The only factor found
so far which influences the spontaneously established
equilibrium is the specific Complex I inhibitor
w xrotenone 122 which partially protects and partially
reverses the thermally induced deactivation. It has
been shown that rotenone has almost two order of
magnitude higher affinity for the active form of the
enzyme. An extremely tight binding of rotenone to
the active enzyme suggests that the inhibitor acts as a
w xtransition state analogue 122 .
4.4. Acti˝ation
As shown in Fig. 3, there are two routs for the
transformation of deactivated enzyme into its active
form. One, which is substrate-independent, includes
slow equilibration within the closed reaction se-
quence 1-5-6-7 and proceeds to significant extend
w xonly in the presence of the rotenone 122 . The other
 .reaction 2 , which is also slow proceeds via a
turnover-dependent mechanism. Oxidation of NADH
 a iby the active enzyme the reaction rates ˝ and ˝t“‘
.shown in Fig. 2 is insensitive to NEM or other
sulfhydryl reagents and to the presence of bivalent
cations. In contrast, the reactions catalyzed by the
deactivated preparations are blocked when the en-
zyme is treated with SH-reagents prior to the addition
of NADH. The lag-phases are considerably prolonged
in the presence of bivalent cations or at alkaline pH
w x 134 . Thus, the activation process reactions 1 and 2,
.Fig. 3 , not the catalytic mechanism of the steady-state
 .NADH oxidation reactions 3 and 4, Fig. 3 , are
sensitive to those effectors. Deactivated enzyme re-
tains its capacity to catalyze all NADH–artificial
acceptor reductase reactions and shows the same
pattern of the iron–sulfur clusters reduction by NADH
w xas seen in the active form 70 . Injection of reducing
equivalents from the substrate–nucleotide NADH or
.NADPH is an absolute prerequisite for further trans-
formation of the enzyme into its active form via
reaction 2. On the other hand, prolonged preincuba-
tion under the condition where the ubiquinone pool is
completely reduced anaerobically or in the presence
.of succinate and antimycin A or cyanide does not
w xresult in activation 27 . No activation was observed
when the enzyme was preincubated with NADq or
ADP-ribose thus showing that binding of nucleotide
and oxidized quinone per se with no further oxidore-
.duction does not induce the conformational transfor-
mation into the active form. On the other hand,
complete activation was observed when deactivated
SMP were incubated in the presence of sub-stoichio-
metric concentrations of NADH and a NADH regen-
w xerating system 27 . Taken together these findings
suggest that at least one slow half-turnover is needed
for transformation of thermodynamically stable inac-
tive enzyme into the thermodynamically unstable but
catalytically competent form. When active enzyme
catalyzes oxidation of NADH by ubiquinone the re-
dox potential gap between the substratesrproducts
 w x w xpairs y320 mV 101 and q60 mV 135 , respec-
.tively provides free energy for transmembranous
qproton transfer and creates Dm . The same reactionH
when performed by the deactivated form results in
conservation of free energy as a constrained enzyme
conformation. In other words, the existence of the
 .equilibria 1 and 2 Fig. 3 suggests that part of the
free energy of NADH oxidation is used to maintain
the catalytically competent state of the enzyme. This
conclusion leads to further consequences.
First, both spontaneous deactivation and redox-de-
pendent activation are slow processes compared to
the active enzyme turnover in reactions 3 and 4 the
.first order rate constants are in a minute scale , hence
it seems unlikely that a combination of the reactions
2 and 1 contributes significantly to the steady-state
rate of NADH oxidation. It does not, however seem
unlikely that this ‘futile’ cyclic transformation con-
tributes to the fine tuning of the main entry point for
the energy-producing respiratory chain. It has been
demonstrated that a different degree of enzyme acti-
vation is attained during the overall NADH oxidation
by SMP at different levels of ubiquinone reduction or
by Complex I in the presence of exogenous Q and1
w xdifferent level of the bacterial quinol oxidase 136 .
In contrast to the spontaneous deactivation and to the
reaction catalyzed by the active enzyme, the redox-
dependent activation was shown to be sensitive to a
number of factors of the potentially physiological
w xsignificance, such as pH and bivalent cations 134 .
The appearance of a highly reactive sulfhydryl in the
deactivated form can also be considered as a chemi-
cal prerequisite for the possible modulation of the
total enzyme activity via naturally existing SH–rS–S
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compounds such as intramitochondrial glutathione
w x137 .
The second point relevant to the redox-dependent
activation is the reversibility of the Complex I-cata-
 .lyzed reactions see Section 2.7 . Since maintenance
of the active enzyme needs energy provided by the
NADH–ubiquinone oxidoreduction it is hard to ac-
cept that the enzyme operates as a simple catalytic
unit equilibrating NADHrNADq, QrQH and2
Dm q, unless the reaction 2 is reversible. The obser-H
vations of different rotenone-sensitivity of the direct
w xand reverse electron transfer 122 and of unidirec-
w xtional competitive inhibition of NADH oxidation 26
suggest that different binding sites for substrates
 .products operate in either reaction. In a strict sense
this would mean that the mechanisms of the direct
and reverse reactions are different as has been sug-
gested for another ‘reversible’ energy-transducing
w xcomplex—F –F ATP synthase 138 .o 1
The molecular mechanism of the enzyme
activerinactive transition is a ‘black box’. Besides
the complete change in the catalytic capacity, several
other features such as strong temperature-depen-
dence, dramatic change in the sulfhydryl reactivity
and affinity to rotenone indicate that gross conforma-
tional changes are involved in the specific alteration
 .in the ubiquinone reactivity. Since ubisemiquinone s
 .are now accepted as intermediate s of the steady-state
NADH “ Q and QH “ NADq activities2
w x  .39,70,139,140 the reaction 2 Fig. 3 mechanisti-
cally can be visualized as follows:
where indexes red, ox stand for the reduced, oxi-
dized, deactivated and active enzyme, respectively.
The deactivated, NADH–reduced enzyme is oxidized
by quinone in one-electron reaction iron–sulfur clus-
w x.ter N-2 is most likely involved 11,39,140 coupled
with a slow rearrangement of the protein resulting in
 .the formation of ubisemiquinone s at specific bind-
 .ing site s . In the absence of further electron flow
through the enzyme the ubisemiquinones dismutate
leaving constrained active enzyme conformation.
It is of interest that the ‘turnover-dependent’ acti-
vation appears not to be a unique property of Com-
plex I; it has been reported that heterodimeric Fe–S,
Ni-containing hydrogen–quinone oxidoreductase of
w xAlcaligenes eutropus 141 , Azotobacter ˝inelandi
w x w x142 and Brodhyrhizobium japonicum 143 demon-
strate quite similar phenomena.
5. Conclusion and perspectives
Despite recent revived interest in molecular struc-
ture and mechanisms of the mammalian, microbial,
fungal and plant Complex I, it is hard to deny that
little progress has been achieved over the last twenty
years in answering several key questions such as the
sequence of the intramolecular electron transfer reac-
tions, the number of proton-translocating sub-sites the
minimal unit retaining the catalytic activities seen in
intact systems. In the author’s opinion much more
work is needed in isolation of ‘pure unmodified’
enzyme capable of the redox-linked proton transloca-
tion in proteoliposomes. The lack of specific in-
hibitors and artificial electron acceptorsrdonors in-
teracting at the sites different from those of nu-
cleotide and quinone binding severely hampers the
creation of new models and delineation of the path as
was done for Complex III. Simpler counterparts of
the mammalian 42-subunit Complex I such as, for
w xexample, P. denitrificans 14–20-subunit NDH-1 5
are now available for molecular genetic manipulation.
The comparative investigation of the mammalian and
simpler bacterial enzymes would be a great help in
understanding of the individual subunits functions. It
is beyond doubt that further studies of the catalytic
properties of the presently available and future prepa-
rations will facilitate progress in the field.
Acknowledgements
I am grateful to my colleagues, past and present,
Drs. D.Sh. Burbaev, E.V. Gavrikova, V.G. Griven-
nikova, A.B. Kotlyar, E.O. Maklashina, V.D. Sled
and T.V. Zharova for many stimulating discussions.
Thanks are due to Ms. N. Zakharova for contributing
in determination of some activities listed in Table 1.
Many helpful discussion with members of a collabo-
( )A.D. Vinogrado˝rBiochimica et Biophysica Acta 1364 1998 169–185 183
rating group led by Dr. T. Ohnishi Department of
Biophysics and Biochemistry, School of Medicine,
.University of Pennsylvania are gratefully acknowl-
edged. Work in the author’s laboratory is supported
 .by the National Institute of Health USA , Fogarty
International Research Collaborative Grant R03
TW00140-01A2 to Dr. T. Ohnishi and A.D.V. and by
the Russian Foundation for Fundamental Research
 .grant 96-04-48185 . The author is supported by the
Program of Advanced Schools in Science grant 96-
.15-97822 . I am also grateful to an anonymous re-
viewer for thorough reading of the manuscript and
many helpful comments.
References
w x  .1 T.P. Singer, M. Gutman, Adv. Enzymol. 34 1971 79–153.
w x  .2 C.I. Ragan, Biochim. Biophys. Acta 456 1976 249–290.
w x3 I.M. Fearnley, J.F. Walker, Biochim. Biophys. Acta 1140
 .1992 105–134.
w x4 H. Weiss, T. Friedrich, G. Hofhaus, D. Preis, Eur. J.
 .Biochem. 197 1991 563–576.
w x  .5 T. Yagi, Biochim. Biophys. Acta 1141 1993 1–17.
w x6 N.A. Rao, S.P. Felton, F.M. Huennekens, B. Mackler, J.
 .Biol. Chem. 238 1963 449–455.
w x  .7 T. Ohnishi, in: R.A. Capaldi Ed. , Membrane Proteins in
Energy Transduction, Dekker, New York, 1979, pp. 1–87.
w x  .8 T. Ohnishi, J.C. Salerno, in: T. Spiro Ed. , Iron–Sulfur
Proteins, Vol. IV, Wiley, New York, 1982, pp. 285–327.
w x9 H. Beinert, S.P.J. Albracht, Biochim. Biophys. Acta 683
 .1982 245–277.
w x10 V.D. Sled, T. Friedrich, H. Leif, H. Weiss, S.W. Mein-
hardt, Y. Fukumori, M. Calhoun, R.B. Gennis, T. Ohnishi,
 .J. Bioenerg. Biomembr. 25 1993 347–356.
w x11 A.D. Vinogradov, V.D. Sled, D.S. Burbaev, V.G. Griven-
 .nikova, I.A. Moroz, T. Ohnishi, FEBS Lett. 370 1995
83–87.
w x  .12 E.A. Berry, B.L. Trumpower, in: G. Lenaz Ed. , Coen-
zyme Q, Wiley, New York, 1985, pp. 365–389.
w x  .13 C.-A. Yu, L. Yu, J. Bioenerg. Biomembr. 25 1993 259–
274.
w x  .14 R. Gennis, S. Ferguson-Miller, Science 269 1995 1063–
1065.
w x15 T. Tsukihara, H. Aoyama, E. Yamashita, T. Tomizaki, H.
Yamaguchi, K. Shinza-Itoh, R. Nakashima, R. Yano, S.
 .Yoshikawa, Science 269 1995 1069–1074.
w x  .16 U. Brandt, Biochim. Biophys. Acta 1318 1997 79–91.
w x  .17 J.E. Walker, Q. Rev. Biophys. 25 1992 253–324.
w x  .18 Y. Hatefi, Methods Enzymol. 53 1978 3–4.
w x  .19 T.P. Singer, R.R. Ramsay, in: L. Ernster Ed. , Molecular
Mechanisms in Bioenergetics, Elsevier, Amsterdam, 1992,
pp. 145–162.
w x20 T. Friedrich, P. Van Heek, H. Leif, T. Ohnishi, E. Forche,
B. Kunze, R. Jansen, W. Trowitzsch-Keinast, G. Hofle, H.¨
 .Reichenbach, H. Weiss, Eur. J. Biochem. 219 1994 691–
698.
w x21 M. Degli Esposti, A. Ghelli, M. Ratta, D. Cortes, E.
 .Estornell, Biochem. J. 301 1994 161–167.
w x22 W. Oettmeier, K. Masson, M. Soll, Biochim. Biophys.
 .Acta 1099 1992 262–266.
w x23 T. Satoh, H. Miyoshi, K. Sakamoto, H. Iwamura, Biochim.
 .Biophys. Acta 1273 1996 21–30.
w x  .24 E.A. Kean, Biochem. Pharmacol. 19 1970 2201–2210.
w x25 E.A. Kean, M. Gutman, T.P. Singer, J. Biol. Chem. 246
 .1971 2346–2353.
w x26 T.V. Zharova, A.D. Vinogradov, Biochim. Biophys. Acta
 .1320 1997 256–264.
w x27 A.B. Kotlyar, A.D. Vinogradov, Biochim. Biophys. Acta
 .1019 1990 151–158.
w x28 T.E. King, R.L. Howard, J. Kettman, B.M. Hegdekar, M.
Kuboyama, K.S. Mickel, E.A. Possehl, in: E.C. Slater
 .Ed. , Flavins and Flavoproteins, Elsevier, Amsterdam,
1966, pp. 441–481.
w x  .29 T. Cremona, E.B. Kearney, J. Biol. Chem. 239 1964
2328–2334.
w x  .30 T.E. King, R.L. Howard, J. Biol. Chem. 237 1962 1686–
1698.
w x31 R.F. Baugh, T.E. King, Biochem. Biophys. Res. Commun.
 .49 1972 1165–1173.
w x32 C. Paech, J.G. Reynolds, T.P. Singer, R.H. Holm, J. Biol.
 .Chem. 256 1981 1922–1927.
w x33 M. Finel, J.M. Skehel, S.P.J. Albracht, I.M. Fearnley, J.E.
 .Walker, Biochemistry 31 1992 11425–11434.
w x  .34 B. Mackler, Biochim. Biophys. Acta 50 1961 141–146.
w x35 R.L. Pharo, L.A. Sordahl, S.R. Vyas, D.R. Sanadi, J. Biol.
 .Chem. 241 1966 4771–4780.
w x  .36 Y. Hatefi, K.E. Stempel, J. Biol. Chem. 244 1969 2350–
2357.
w x  .37 A.D. Vinogradov, J. Bioenerg. Biomembr. 25 1993 367–
375.
w x38 V.D. Sled, A.D. Vinogradov, Biochim. Biophys. Acta 1141
 .1993 262–268.
w x39 D.S. Burbaev, I.A. Moroz, A.B. Kotlyar, V.D. Sled, A.D.
 .Vinogradov, FEBS Lett. 254 1989 47–51.
w x  .40 C.P. Lee, L. Ernster, Methods Enzymol. 10 1967 543–
548.
w x  .41 Y. Hatefi, J.S. Rieske, Methods Enzymol. 10 1967 225–
231.
w x  .42 T.E. King, Methods Enzymol. 10 1967 202–208.
w x  .43 A.D. Vinogradov, T.E. King, Methods Enzymol. 55 1979
118–127.
w x44 Y.-P. Wan, R.H. Williams, K. Folker, K.H. Leung, E.
 .Racker, Biochem. Biophys. Res. Commun. 63 1975 11–
15.
w x  .45 G. Schatz, E. Racker, J. Biol. Chem. 241 1966 1429–
1437.
w x  .46 H.G. Lawford, P.B. Garland, Biochem. J. 130 1971
1029–1044.
( )A.D. Vinogrado˝rBiochimica et Biophysica Acta 1364 1998 169–185184
w x  .47 C.I. Ragan, P.C. Hinkle, J. Biol. Chem. 250 1975 8472–
8480.
w x48 L. Helfenbaum, A. Ngo, A. Ghelli, A.W. Linnane, M.
 .Degli Esposti, J. Bioenerg. Biomembr. 29 1997 71–80.
w x  .49 L.R. Fowler, S.H. Richardson, J. Biol. Chem. 238 1963
456–463.
w x  .50 C.I. Ragan, C. Heron, Biochem. J. 174 1978 783–790.
w x  .51 P. Mitchell, FEBS Lett. 56 1975 1–6.
w x52 M. Degli Esposti, A. Chelli, M. Crimi, E. Estronell, R.
Fato, G. Lenaz, Biochem. Biophys. Res. Commun. 190
 .1993 1090–1096.
w x53 M. Degli Esposti, M. Crimi, A. Ghelli, Biochem. Soc.
 .Trans. 22 1994 209–212.
w x54 A.K. Tan, R.R. Ramsay, T.P. Singer, H. Miyoshi, J. Biol.
 .Chem. 268 1993 19328–19333.
w x55 J.A. Morgan-Hughes, A.H.V. Shapira, J.M. Cooper, I.J.
Holt, A.E. Harding, J.B. Clark, Biochim. Biophys. Acta
 .1018 1990 217–222.
w x56 E. Estronell, R. Fato, F. Pallotti, G. Lenaz, FEBS Lett. 332
 .1993 127–131.
w x57 M.L. Genova, C. Castelluccio, R. Fato, G. Parenti Castelli,
M. Merlo Pich, G. Formiggini, C. Bovina, M. Marchetti,
 .G. Lenaz, Biochem. J. 311 1995 105–109.
w x  .58 T.P. Singer, Methods Biochem. Anal. 22 1974 123–175.
w x59 T. Ohnishi, C.I. Ragan, Y. Hatefi, J. Biol. Chem. 260
 .1985 2782–2788.
w x60 G. Dooijewaard, E.C. Slater, Biochim. Biophys. Acta 440
 .1976 1–15.
w x61 G. Dooijewaard, E.C. Slater, Biochim. Biophys. Acta 440
 .1976 16–35.
w x62 Y. Hatefi, Y.M. Galante, Proc. Natl. Acad. Sci. U.S.A. 74
 .1977 846–850.
w x63 E.V. Gavrikova, V.G. Grivennikova, V.D. Sled, T. Ohnishi,
 .A.D. Vinogradov, Biochim. Biophys. Acta 1230 1995
23–30.
w x64 P.C. Hinkle, R.A. Butow, E. Racker, B. Chance, J. Biol.
 .Chem. 242 1967 5169–5173.
w x  .65 A. Boveris, E. Cadenas, FEBS Lett. 54 1975 311–314.
w x  .66 B. Chance, H. Sies, A. Boveris, Physiol. Rev. 59 1979
527–605.
w x  .67 J.F. Turrens, A. Boveris, Biochem. J. 191 1980 421–427.
w x68 V. Massey, S. Strickland, S.G. Mayhew, L.G. Howell, P.C.
Engel, R.G. Matthews, M. Schuman, P.A. Sullivan,
 .Biochem. Biophys. Res. Commun. 36 1969 891–897.
w x  .69 I. Fridovich, Adv. Enzymol. 41 1974 35–97.
w x70 A.B. Kotlyar, V.D. Sled, D.S. Burbaev, I.A. Moroz, A.D.
 .Vinogradov, FEBS Lett. 264 1990 17–20.
w x  .71 K. Takeshige, S. Minakami, Biochem. J. 180 1979 129–
135.
w x72 D. Kang, H. Narabayashi, T. Sata, K. Takeshige, J.
 .  .Biochem. Tokyo 94 1983 1301–1306.
w x  .73 G. Krishnamoorthy, P. Hinkle, J. Biol. Chem. 263 1988
17566–17575.
w x  .74 P.C. Chan, B.H.J. Bielski, J. Biol. Chem. 249 1974
1317–1319.
w x  .75 P.C. Chan, B.H.J. Bielski, J. Biol. Chem. 255 1980
874–876.
w x  .76 B. Halliwell, FASEB J. 1 1987 358–364.
w x  .77 R. Luft, Proc. Natl. Acad. Sci. U.S.A. 91 1994 8731–
8738.
w x  .78 V.D. Sled, B.H. Zinich, A.B. Kotlyar, Biokhimia USSR
 .54 1989 1571–1576.
w x79 C.P. Lee, N. Sigmard-Duquesne, H. Hoberman, L. Ernster,
 .Biochim. Biophys. Acta 105 1965 397–408.
w x80 L. Ernster, H. Hoberman, R.L. Howard, T.E. King, C.P.
 .Lee, B. Mackler, G. Sottocasa, Nature 207 1965 940–941.
w x81 S. Chen, R.J. Guillory, Biochem. Biophys. Res. Commun.
 .129 1985 584–590.
w x82 L. Ernster, R.W. Estabrook, P. Hochstein, S. Orrenius,
 .Chem. Scr. 27 1987 1–207.
w x83 R. Li, M.A. Bianchet, P. Talalay, L.M. Amzel, Proc. Natl.
 .Acad. Sci. U.S.A. 92 1995 8846–8850.
w x84 V.D. Sled, N.I. Rudnitzky, Y. Hatefi, T. Ohnishi, Bio-
 .chemistry 33 1994 10069–10075.
w x85 V.D. Sled, A.D. Vinogradov, Biochim. Biophys. Acta 1143
 .1993 199–203.
w x  .86 L. Djavadi-Ohaniance, Y. Hatefi, J. Biol. Chem. 250 1975
9397–9403.
w x87 J. Rydstrom, J. Montelius, D. Backstrom, L. Ernster,¨ ¨ ¨
 .Biochim. Biophys. Acta 501 1978 370–380.
w x88 C.I. Ragan, W.R. Widger, T.E. King, Biochem. Biophys.
 .Res. Commun. 3 1974 894–900.
w x  .89 H. Low, I. Vallin, Biochim. Biophys. Acta 69 1963¨
361–374.
w x90 P.T.A. Bakker, S.P.J. Albracht, Biochim. Biophys. Acta
 .850 1986 413–422.
w x91 R. van Belzen, S.P.J. Albracht, Biochim. Biophys. Acta
 .974 1989 311–320.
w x92 R. van Belzen, M.C.M. van Gaalen, P.A. Cuypers, S.P.J.
 .Albracht, Biochim. Biophys. Acta 1017 1990 152–159.
w x93 S.P.J. Albracht, A.M.P. de Jong, Biochim. Biophys. Acta
 .1318 1997 92–106.
w x94 M.A. Glinn, C.P. Lee, L. Ernster, Biochim. Biophys. Acta
 .1318 1997 246–254.
w x  .95 S. Chen, R.J. Guillory, J. Biol. Chem. 256 1981 8318–
8323.
w x  .96 P.S.K. Deng, Y. Hatefi, S. Chen, Biochemistry 29 1990
1094–1098.
w x  .97 T. Yagi, T.M. Dinh, Biochemistry 29 1990 5515–5520.
w x98 X.-M. Xu, T. Yagi, Biochem. Biophys. Res. Commun. 174
 .1991 667–672.
w x99 D. Preis, J.C. Van der Pas, U. Nehls, D.-A. Rohlen, U.¨
Sackmann, U. Jahnke, H. Weiss, Biochim. Biophys. Acta
 .1089 1991 389–390.
w x100 D.A. Rohlen, J. Hoffmann, J.C. Van der Pas, U. Nehls, D.¨
 .Preis, U. Sackman, H. Weiss, FEBS Lett. 278 1991
75–78.
w x101 W.M. Clark, Oxidation Reduction Potentials of Organic
Systems, Williams & Wilkins, Baltimore, 1960.
w x  .102 D.R. Sanadi, A.L. Fluharty, Biochemistry 2 1963 523–
528.
w x103 V.G. Grivennikova, E.V. Gavrikova, A.A. Timoshin, A.D.
 .Vinogradov, Biochim. Biophys. Acta 1140 1993 282–
292.
( )A.D. Vinogrado˝rBiochimica et Biophysica Acta 1364 1998 169–185 185
w x104 A. Sucheta, B.A.C. Ackrell, B. Cochran, F.A. Armstrong,
 .Nature 356 1992 361–362.
w x105 V.G. Grivennikova, A.D. Vinogradov, Biochim. Biophys.
 .Acta 682 1982 491–495.
w x106 P.R. Tushurashvili, E.V. Gavrikova, A.N. Ledenev, A.D.
 .Vinogradov, Biochim. Biophys. Acta 809 1985 145–159.
w x  .107 B. Chance, G. Hollunger, Nature 185 1960 666–672.
w x  .108 M. Klingenberg, W. Slenczka, Biochem. Z. 331 1959
486–517.
w x109 Proceedings of the Fifth International Congress of Bio-
chemistry, Vol. 5, Pergamon, Oxford, 1963.
w x  .110 B. Chance Ed. , Energy-Linked Functions of Mitochon-
dria, Academic Press, New York, 1963.
w x  .111 R. Beyer, Methods Enzymol. 10 1967 186–196.
w x  .112 M.B. Thorn, Biochem. J. 85 1962 116–127.
w x113 A.B. Kotlyar, A.D. Vinogradov, Biochim. Biophys. Acta
 .784 1984 24–34.
w x114 B.A.C. Ackrell, E.B. Kearney, D.E. Edmondson, J. Biol.
 .Chem. 250 1975 7114–7119.
w x115 E.A. Vasilyeva, I.B. Minkov, A.F. Fitin, A.D. Vinogradov,
 .Biochem. J. 202 1982 9–14.
w x116 E.A. Vasilyeva, A.F. Fitin, I.B. Minkov, A.D. Vinogradov,
 .Biochem. J. 188 1980 807–815.
w x117 L. Ernster, C. Carlsson, T. Hundal, K. Nordenbrand, Meth-
 .ods Enzymol. 55 1979 399–407.
w x  .118 M.V. Panchenko, A.D. Vinogradov, FEBS Lett. 184 1985
226–230.
w x  .119 F.A. Hommes, Biochim. Biophys. Acta 77 1963 173–182.
w x  .120 E. Racker, L. Horstman, J. Biol. Chem. 242 1967 2547–
2556.
w x121 A.B. Kotlyar, M. Gutman, Biochim. Biophys. Acta 1140
 .1992 169–174.
w x122 V.G. Grivennikova, E.O. Maklashina, E.V. Gavrikova,
 .A.D. Vinogradov, Biochim. Biophys. Acta 1319 1997
223–232.
w x123 M. Lazdunski, D. Petitclere, D. Chappelet, C. Lazdunski,
 .Eur. J. Biochem. 20 1971 124–135.
w x  .124 E.C. Slater, Biochem. J. 46 1950 499–503.
w x  .125 R.O. Morrison, T.E. King, Biochemistry 1 1962 1017–
1024.
w x126 S. Minakami, F.J. Schindler, R.W. Estabrook, J. Biol.
 .Chem. 239 1964 2049–2054.
w x127 V.N. Luzikov, V.A. Saks, I.V. Berezin, Biochim. Biophys.
 .Acta 223 1970 16–30.
w x128 V.N. Luzikov, L.V. Romashina, Biochim. Biophys. Acta
 .267 1972 37–47.
w x129 V.A. Saks, V.V. Kupriyanov, V.N. Luzikov, Biochim.
 .Biophys. Acta 283 1972 42–53.
w x130 E.R. Redfearn, P.A. Whittaker, J. Burgos, in: T.E. King,
 .H.S. Mason, M. Morrison Eds. , Oxidases and Related
Redox Systems, Wiley, New York, 1965, pp. 943–959.
w x131 S. Minakami, F.J. Schindler, R.W. Estabrook, J. Biol.
 .Chem. 239 1964 2042–2048.
w x132 R.W. Estabrook, D.D. Tyler, J. Gonze, J.A. Peterson, in:
 .K. Yagi Ed. , Flavins and Flavoproteins, University of
Tokyo Press, Tokyo, 1968, pp. 268–279.
w x133 E.O. Maklashina, V.D. Sled, A.D. Vinogradov, Biochem-
 .  .istry Moscow 59 1994 707–714.
w x134 A.B. Kotlyar, V.D. Sled, A.D. Vinogradov, Biochim. Bio-
 .phys. Acta 1098 1992 144–150.
w x135 M. Erecinska, D.F. Wilson, Arch. Biochem. Biophys. 174
 .1967 143–157.
w x136 E.O. Maklashina, A.D. Vinogradov, Biochemistry
 .  .Moscow 59 1994 1221–1226.
w x  .137 D. Dolphin, R. Poulson, O. Avramovic Eds. , Glutathione:
Chemical, Biochemical and Medical Aspects, Wiley, New
York, 1989.
w x138 A.V. Syroeshkin, E.A. Vasilyeva, A.D. Vinogradov, FEBS
 .Lett. 366 1995 29–32.
w x139 A.M.P. De Jong, S.P.J. Albracht, Eur. J. Biochem. 222
 .1994 975–982.
w x140 R. van Belzen, A.B. Kotlyar, N. Moon, R. Dunham, S.P.
 .Albracht, Biochemistry 36 1997 886–893.
w x141 K. Schneider, D.S. Patil, R. Cammack, Biochim. Biophys.
 .Acta 748 1983 353–361.
w x  .142 J.-H. Sun, D.J. Arp, Arch. Biochem. Biophys. 287 1991
225–233.
w x143 D.M. Ferber, B. Moy, R. Maier, Biochim. Biophys. Acta
 .1229 1995 334–346.
